19/01/2022
A research team led by Dr. Marcus Koch and Dr. Wee Yong (Co-Founder and Chief Scientific Officer of AnthoBio) at the University of Calgary that investigates a generic drug, hydroxychloroquine, in primary progressive multiple sclerosis (PPMS) recently published its clinical study results in Annals of Neurology. The study followed 35 PPMS patients over a period of five years. Throughout the study, 14 patients were expected to develop a significant reduction in their walking function. However, only 8 patients had experienced a reduction by the end of the study. That’s almost a 50% reduction in the number of PPMS patients negatively affected by continuing disability. Although the results will require confirmation in a larger trial, this study has shown that hydroxychloroquine could help slow down the disability progression of PPMS. This study opens the possibility for future treatment option for PPMS and the researchers hope their work will inspire future larger scale clinical research on the drug for PPMS.
For more information, please refer to the University of Calgary’s article: https://ucalgary.ca/news/study-finds-hydroxychloroquine-delays-disability-least-treatable-form-multiple-sclerosis?mkt_tok=MTYxLU9MTi05OTAAAAGB-GYDoPf-ARTvBhGYh_4JhGLu4v6ix7hAOwgNlblydTqMJB4CDvTa6XslccOhUtE2XL53aDcTP11EstVJzm45GGwSqOhk8ohtDs2EjELw0P5glzY
or a short video on YouTube: https://www.youtube.com/watch?v=09pgJP3SElE
We strive to understand the value that natural health products/dietary supplements bring to MS patients. Please share your experiences with us through this short survey. The survey is anonymous and will only take less than 2 mins to complete.
Survey link: https://docs.google.com/forms/d/e/1FAIpQLSeb1GYpw-vnusfOTAAyMYFnTmzBBQeF6zgvei4lLOt3W-v8bg/viewform
Research results open door for potential larger-scale study of generic drug for MS